Chand, Deepa H.
Washington University in St. Louis · Novartis Gene Therapies, Inc. (United States)
4 papers on CoChatORCID 0000-0002-0745-9338
Most cited papers
- Verified
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
Day, J. W., Finkel, R. S., Chiriboga, C. A., Connolly, A. M., Crawford, T. O., Darras, B. T., Iannaccone, S. T., Kuntz, N. L., Peña, L. D. M., Shieh, P. B., et al. (2021) · The Lancet Neurology
Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy research
Cited by 494
- Verified
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Chand, D., Mohr, F., McMillan, H., Tukov, F. F., Montgomery, K., Kleyn, A., Sun, R., Tauscher-Wisniewski, S., Kaufmann, P., & Kullak-Ublick, G. (2021) · Journal of Hepatology
Neurogenetic and Muscular Disorders ResearchDrug-Induced Hepatotoxicity and Protection
Cited by 306
- Verified
Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series
Chand, D. H., Zaidman, C., Arya, K., Millner, R., Farrar, M. A., Mackie, F. E., Goedeker, N. L., Dharnidharka, V. R., Dandamudi, R., & Reyna, S. P. (2021) · The Journal of Pediatrics
Complement system in diseasesNeurogenetic and Muscular Disorders Research
Cited by 210
- Verified
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety
Neurogenetic and Muscular Disorders ResearchVirus-based gene therapy research
Cited by 119
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free